Description
Mevastatin is an HMG-CoA reductase inhibitor that exhibits anti-hyperlipidemic, anticancer, and immunomodulatory activities. Mevastatin induces apoptosis and inhibits growth of salivary adenoid cystic carcinoma cells by increasing cytochrome c release, activation of caspase 3, and phosphorylation of JNK, p38 MAPK, and ERK1/2. In other models, mevastatin inhibits bisphosphonate-induced activation of γδ T cells and release of TNF-α.
References
Zhang S, Wang XL, Gan YH, et al. Activation of c-Jun N-terminal kinase is required for mevastatin-induced apoptosis of salivary adenoid cystic carcinoma cells. Anticancer Drugs. 2010 Aug;21(7):678-86. PMID: 20629200.
Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res. 2004 Feb;19(2):278-88. PMID: 14969398.
Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976 Dec;29(12):1346-8. PMID: 1010803.